Annual report
3341.TEDINET S100TSE7
Period2023-04-01 → 2024-03-31
Filed2024-06-26
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Amended by S100W69I (2025-06-26).
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥340.3bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales |
| Revenue | ¥313.3bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales |
| Revenue | ¥299.4bn | 2021-04-01 → 2022-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥279.0bn | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥268.5bn | 2019-04-01 → 2020-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥9.1bn | 2023-04-01 → 2024-03-31 | Cons. | Operating income |
| Operating income | ¥7.6bn | 2022-04-01 → 2023-03-31 | Cons. | Operating income |
| Ordinary income | ¥9.4bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥7.7bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥6.8bn | 2021-04-01 → 2022-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥8.4bn | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥7.4bn | 2019-04-01 → 2020-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥5.1bn | 2023-04-01 → 2024-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥7.8bn | 2022-04-01 → 2023-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥2.6bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥4.5bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥3.7bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥3.5bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥6.7bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥2.6bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss |
| Net income | ¥4.5bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss |
| Total assets | ¥195.1bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥185.3bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥178.8bn | at 2022-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥186.3bn | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥185.6bn | at 2020-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥136.7bn | at 2024-03-31 | Cons. | Liabilities |
| Total liabilities | ¥128.8bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥58.4bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥56.5bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥52.9bn | at 2022-03-31d | Cons. | Net assets |
| Net assets / equity | ¥49.9bn | at 2021-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥47.1bn | at 2020-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥26.0bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥23.8bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥26.0bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥23.8bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥25.5bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥32.9bn | at 2021-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥32.3bn | at 2020-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥20.4bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥7.5bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥19.4bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥11.2bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥13.2bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥13.7bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥10.0bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥9.3bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥7.8bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥2.7bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥4.4bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥713m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥17.4bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥2.8bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥8.0bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥85.35 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥148.92 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥123.56 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥118.01 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥223.33 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥1,950.44 | at 2024-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,888.17 | at 2023-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,763.34 | at 2022-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,663.01 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,569.77 | at 2020-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 29.9% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 30.5% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 29.6% | at 2022-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 26.8% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 25.4% | at 2020-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 4.5% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.2% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.2% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.3% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 15.2% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 5,864 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 5,689 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 5,552 | at 2022-03-31d | Cons. | Number of employees |
| Employees | 5,221 | at 2021-03-31d | Cons. | Number of employees |
| Employees | 4,904 | at 2020-03-31d | Cons. | Number of employees |
| Revenue | ¥298.0bn | 2023-04-01 → 2024-03-31 | Standalone | Net sales |
| Revenue | ¥275.3bn | 2022-04-01 → 2023-03-31 | Standalone | Net sales |
| Revenue | ¥259.2bn | 2021-04-01 → 2022-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥233.6bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥223.8bn | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥7.8bn | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Operating income | ¥7.9bn | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Ordinary income | ¥8.6bn | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥8.6bn | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥6.6bn | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥7.0bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥5.3bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥5.4bn | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥6.2bn | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Net income | ¥3.0bn | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥3.2bn | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥2.3bn | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥3.5bn | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥4.7bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥155.7bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥148.3bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥140.1bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥145.5bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥144.9bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥111.9bn | at 2024-03-31 | Standalone | Liabilities |
| Total liabilities | ¥106.7bn | at 2023-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥43.8bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥41.5bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥39.2bn | at 2022-03-31d | Standalone | Net assets |
| Net assets / equity | ¥37.7bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥34.9bn | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥18.3bn | at 2024-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥19.1bn | at 2023-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥99.76 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥105.35 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥77.25 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥116.69 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥155.83 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥25 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥25 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥25 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥25 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥50 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,462.94 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,388.25 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,308.05 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,255.8 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,164.12 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 28.1% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 28.0% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 28.0% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 25.9% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 24.1% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 7.0% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 7.8% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.0% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 9.6% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 14.2% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 31,048,000 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 32,048,000 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 32,048,000 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 32,048,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 16,024,000 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 4,642 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 4,587 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 4,458 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 4,034 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 3,750 | at 2020-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 71
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2023-04-01 → 2024-03-31 | ¥1.1bn |
| Reconciling Itemsreconciling | depreciation | 2023-04-01 → 2024-03-31 | ¥780m |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2024-03-31 | −¥12.9bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2024-03-31 | −¥12.9bn |
| Reconciling Itemsreconciling | segment assets | at 2024-03-31 | ¥3.3bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2024-03-31 | −¥7.2bn |
| Dispensing Pharmacy Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥8.9bn |
| Dispensing Pharmacy Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥2.8bn |
| Dispensing Pharmacy Businessreportable segment | employees | at 2024-03-31 | 4395 pure |
| Dispensing Pharmacy Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥302.8bn |
| Dispensing Pharmacy Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥302.8bn |
| Dispensing Pharmacy Businessreportable segment | segment assets | at 2024-03-31 | ¥115.7bn |
| Dispensing Pharmacy Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥15.2bn |
| Medical Professional Staffing And Placement Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥83m |
| Medical Professional Staffing And Placement Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥147m |
| Medical Professional Staffing And Placement Businessreportable segment | employees | at 2024-03-31 | 306 pure |
| Medical Professional Staffing And Placement Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥10.0bn |
| Medical Professional Staffing And Placement Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥9.9bn |
| Medical Professional Staffing And Placement Businessreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥111m |
| Medical Professional Staffing And Placement Businessreportable segment | segment assets | at 2024-03-31 | ¥5.0bn |
| Medical Professional Staffing And Placement Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥937m |
| Pharmaceutical Manufacturing And Sales Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥2.0bn |
| Pharmaceutical Manufacturing And Sales Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥3.5bn |
| Pharmaceutical Manufacturing And Sales Businessreportable segment | employees | at 2024-03-31 | 837 pure |
| Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥40.4bn |
| Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥27.6bn |
| Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥12.8bn |
| Pharmaceutical Manufacturing And Sales Businessreportable segment | segment assets | at 2024-03-31 | ¥71.1bn |
| Pharmaceutical Manufacturing And Sales Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥250m |
| —segment total | capex | 2023-04-01 → 2024-03-31 | ¥11.1bn |
| —segment total | depreciation | 2023-04-01 → 2024-03-31 | ¥6.4bn |
| —segment total | revenue | 2023-04-01 → 2024-03-31 | ¥353.2bn |
| —segment total | revenue external | 2023-04-01 → 2024-03-31 | ¥340.3bn |
| —segment total | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥12.9bn |
| —segment total | segment assets | at 2024-03-31 | ¥191.7bn |
| —segment total | segment profit | 2023-04-01 → 2024-03-31 | ¥16.4bn |
| Reconciling Itemsreconciling | capex | 2022-04-01 → 2023-03-31 | ¥674m |
| Reconciling Itemsreconciling | depreciation | 2022-04-01 → 2023-03-31 | ¥400m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2023-03-31 | −¥13.5bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2023-03-31 | −¥13.5bn |
| Reconciling Itemsreconciling | segment assets | at 2023-03-31 | ¥2.8bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2023-03-31 | −¥6.4bn |
| Dispensing Pharmacy Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥7.5bn |
| Dispensing Pharmacy Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥2.8bn |
| Dispensing Pharmacy Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥280.2bn |
| Dispensing Pharmacy Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥280.2bn |
| Dispensing Pharmacy Businessreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥3m |
| Dispensing Pharmacy Businessreportable segment | segment assets | at 2023-03-31 | ¥107.4bn |
| Dispensing Pharmacy Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥14.7bn |
| Medical Professional Staffing And Placement Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥79m |
| Medical Professional Staffing And Placement Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥95m |
| Medical Professional Staffing And Placement Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥8.1bn |
| Medical Professional Staffing And Placement Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥8.1bn |
| Medical Professional Staffing And Placement Businessreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥10m |
| Medical Professional Staffing And Placement Businessreportable segment | segment assets | at 2023-03-31 | ¥3.9bn |
| Medical Professional Staffing And Placement Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥758m |
| Pharmaceutical Manufacturing And Sales Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥2.0bn |
| Pharmaceutical Manufacturing And Sales Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥3.5bn |
| Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥38.6bn |
| Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥25.1bn |
| Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥13.5bn |
| Pharmaceutical Manufacturing And Sales Businessreportable segment | segment assets | at 2023-03-31 | ¥71.1bn |
| Pharmaceutical Manufacturing And Sales Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | −¥1.4bn |
| —segment total | capex | 2022-04-01 → 2023-03-31 | ¥9.6bn |
| —segment total | depreciation | 2022-04-01 → 2023-03-31 | ¥6.3bn |
| —segment total | revenue | 2022-04-01 → 2023-03-31 | ¥326.8bn |
| —segment total | revenue external | 2022-04-01 → 2023-03-31 | ¥313.3bn |
| —segment total | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥13.5bn |
| —segment total | segment assets | at 2023-03-31 | ¥182.4bn |
| —segment total | segment profit | 2022-04-01 → 2023-03-31 | ¥14.0bn |
| Dispensing Pharmacy Businessreportable segment | employees | at 2024-03-31 | 4316 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,570
| Item | Context | Value | Unit |
|---|---|---|---|
| All employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row2Member | 0.738 | |
| Regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row2Member | 0.757 | |
| Non regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row2Member | 0.571 | |
| Ratio of female employees in managerial positions metrics of consolidated subsidiaries | CurrentYearInstant_Row3Member | 0.256 | |
| All employees ratio of male employees taking childcare leave metrics of consolidated subsidiaries | CurrentYearInstant_Row3Member | 1.000 | |
| All employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row3Member | 0.845 | |
| Regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row3Member | 0.853 | |
| Non regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row3Member | 0.520 | |
| Gross scope1 greenhouse gas emissions scope1 and2 greenhouse gas emissions | Prior2YearDuration_ConsolidatedAccountingGroupMember | 5766 | |
| Gross scope1 greenhouse gas emissions scope1 and2 greenhouse gas emissions | Prior1YearDuration_ConsolidatedAccountingGroupMember | 5454 | |
| Gross scope1 greenhouse gas emissions scope1 and2 greenhouse gas emissions | CurrentYearDuration_ConsolidatedAccountingGroupMember | 5175 | |
| Gross scope2 greenhouse gas emissions scope1 and2 greenhouse gas emissions | Prior2YearDuration_ConsolidatedAccountingGroupMember | 35205 | |
| Gross scope2 greenhouse gas emissions scope1 and2 greenhouse gas emissions | Prior1YearDuration_ConsolidatedAccountingGroupMember | 31612 | |
| Gross scope2 greenhouse gas emissions scope1 and2 greenhouse gas emissions | CurrentYearDuration_ConsolidatedAccountingGroupMember | 25086 | |
| Gross scope3 greenhouse gas emissions | Prior2YearDuration_ConsolidatedAccountingGroupMember | － | |
| Gross scope3 greenhouse gas emissions | Prior1YearDuration_ConsolidatedAccountingGroupMember | 659942 | |
| Gross scope3 greenhouse gas emissions | CurrentYearDuration_ConsolidatedAccountingGroupMember | － | |
| Targets description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row1Member | 13.0 | |
| Performance description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row1Member | 13.3 | |
| Targets description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row2Member | 95.0 | |
| Performance description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row2Member | 97.4 | |
| Targets description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row3Member | 2.7 | |
| Performance description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row3Member | 2.69 | |
| Targets description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row4Member | 2 | |
| Performance description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row4Member | 2 | |
| Research and development expenses research and development activities | CurrentYearDuration | 2765000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration | 12188000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E05422-000DispensingPharmacyBusinessReportableSegmentMember | 8932000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E05422-000PharmaceuticalManufacturingAndSalesBusinessReportableSegmentMember | 2040000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E05422-000MedicalProfessionalStaffingAndPlacementBusinessReportableSegmentMember | 83000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_CorporateSharedMember | 1131000000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 31048000 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 31048000 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 31048000 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 31048000 | |
| Number of shares constituting one unit | CurrentYearInstant_OrdinaryShareMember | 100 | |
| Number of shareholders national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shareholders financial institutions | CurrentYearInstant_OrdinaryShareMember | 13 | |
| Number of shareholders financial service providers | CurrentYearInstant_OrdinaryShareMember | 18 | |
| Number of shareholders other corporations | CurrentYearInstant_OrdinaryShareMember | 81 | |
| Number of shareholders foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 108 | |
| Number of shareholders foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 12 | |
| Number of shareholders individuals and others | CurrentYearInstant_OrdinaryShareMember | 11066 | |
| Number of shareholders total | CurrentYearInstant_OrdinaryShareMember | 11298 | |
| Number of shares held number of units national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shares held number of units financial institutions | CurrentYearInstant_OrdinaryShareMember | 15945 | |
| Number of shares held number of units financial service providers | CurrentYearInstant_OrdinaryShareMember | 3506 | |
| Number of shares held number of units other corporations | CurrentYearInstant_OrdinaryShareMember | 62258 | |
| Number of shares held number of units foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 30805 | |
| Number of shares held number of units foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 49 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |